查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015176

食品動物非治療性抗生素市場：依動物種類、產品類型、劑型、給藥途徑、最終用途及銷售管道分類－2026-2032年全球市場預測

Non-Therapeutic Antibiotics for Food Animals Market by Animal Type, Product Type, Formulation, Application Mode, End Use, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，肉類牲畜非治療性抗生素市場價值58.4億美元，預計2026年將成長至62.4億美元，年複合成長率為7.27%，到2032年將達到95.5億美元。

主要市場統計數據
基準年 2025 58.4億美元
預計年份：2026年 62.4億美元
預測年份 2032 95.5億美元
複合年成長率 (%) 7.27%

在不斷發展的科學、監管和商業性背景下，制定了在食用動物中使用非治療性抗生素的現代策略框架。

全球範圍內關於肉類生產中非治療性抗生素使用的爭論已進入一個更為複雜的階段，這一階段受到科學進步、消費者期望變化以及監管力度加大的影響。價值鏈上的相關人員都面臨著如何在保障生產力和供應連續性的同時，兼顧動物健康管理與合理使用抗菌藥物的原則。本導言重點闡述政策趨勢、產業因應措施和商業性現實之間的相互作用，為後續分析提供背景。

科學發現、消費者期望和技術進步如何融合，從而改變肉類生產中合理使用抗生素的實踐和商業策略？

近年來，畜牧業整體經歷了一系列變革，從根本上改變了人們對非治療性抗生素的認知、監管和使用方式。首先，科學共識和監測數據已將抗菌素抗藥性從一個特殊問題提升為跨領域的公共衛生優先事項，促使獸醫和食品安全機構制定了更完善的管理框架和修訂了相關指南。因此，產業實務也隨之調整，許多大型生產者和零售商正式製定了抗生素使用政策，並加快了替代干預措施的測試。

評估 2025 年關稅調整將如何影響投入品採購、供應彈性和整個價值鏈的合理利用的投資可行性。

2025年實施的關稅政策調整進一步增加了畜牧業相關投入品和成品貿易及供應結構的複雜性，影響了成本結構和採購決策，並間接影響了非治療性抗生素的使用模式。對某些獸用投入品和飼料原料分銷徵收的關稅改變了相對價格，促使一些生產商重新評估其採購區域，並加速了供應多元化策略的實施。這些貿易變化並非孤立存在，而是與國內監管措施和農場層面的經營選擇相互作用。

細分市場的洞察揭示了動物種類、產品類型、給藥方法、預期最終用途、製劑形式和通路如何決定管理途徑和進入障礙。

從精細的細分觀點來看，很明顯，偏離常規非治療性抗生素使用的途徑會因動物種類、產品類型、給藥方法、最終用途、製劑形式和銷售管道的不同而存在顯著差異。基於動物種類，水產養殖、牛、家禽和豬等生產系統各自具有獨特的流行病學特徵、管理節奏和資金需求，這些因素都會影響可行的管理干預措施。家禽和豬的生產系統通常採用更高的飼養密度和更短的生產週期，與牛和水產養殖企業相比，它們面臨不同的壓力和機會。

美洲、歐洲、中東和非洲以及亞太地區的區域法規結構、貿易聯繫和生產系統的多樣性如何影響管理的發展和替代方案的引入路徑？

區域趨勢正深刻影響著監管方式、替代方案的採用以及貿易流動，導致北美、南美、歐洲以及中東和非洲的戰略重點各不相同。在北美，消費者對透明度的重視以及零售商主導的採購方式，推動了自願舉措計劃的開展，同時也促進了國家監管措施的實施。南美的生產商則日益注重使採購慣例與買家需求保持一致，並加強對可追溯性的投入，以維持市場准入和品牌差異化。

深入了解競爭定位和能力叢集：確定哪些公司能夠有效地將替代品商業化，並在整個供應鏈中主導管理實施。

產業主要參與者之間的競爭格局和能力差異正在重塑其管理義務轉化為營運決策的方式。領先的整合商和供應商憑藉其產品創新和強大的分銷網路，更有能力提供能夠減少對常規非治療性抗生素依賴的綜合解決方案。這些公司通常會投資診斷服務、疫苗接種計畫和主導干預措施，幫助客戶順利過渡，同時最大限度地減少生產力損失。中型區域性企業往往在服務接近性和價格方面競爭，其成功與否取決於能否根據當地畜牧業實踐調整其諮詢能力。

為高階主管提供切實可行的優先措施，以減少對常規抗生素的依賴，同時保持生產力（包括診斷、採購重組和跨價值鏈協作）。

產業領導者應優先考慮一系列切實可行的措施，以平衡短期合規要求與長期韌性和競爭力。首先，他們應加強對農場的諮詢服務，並投資快速診斷技術，將決策從「統一的預防措施」轉向「有針對性的治療性介入」。這種方法既能減少不必要的抗生素使用，又能保障動物健康。其次，他們應實現投入來源多元化，並制定籌資策略，優先選擇能夠提供檢驗的管理認證的供應商，以降低關稅和地緣政治因素帶來的供應風險。

本報告提供了高度透明的分析，整合了文獻綜述、相關人員訪談和定性分析，並採用三角測量法來支持所提出的行業特定和操作性結論。

本執行摘要的研究結合了二手文獻綜述、相關人員訪談和結構化定性分析，旨在整合影響肉類畜牧系統中非治療性抗生素使用的最新趨勢。二手資訊包括同行評審的科學文獻、監管指導文件、行業白皮書和公共監測報告，以確保與抗菌素抗藥性、停藥方案和合理使用框架的最新證據保持一致。一手資訊則透過對獸醫、飼料廠經理、經銷商高階主管、各類畜牧生產者和產業專家的訪談收集，以反映實際情況和新興做法。

一項權威的、綜合性的分析，強調以證據為基礎的策略和協作方法，以協調管理目標與生產和商業需求。

總之，肉類生產中常規、非治療性抗生素使用方式的轉變是由科學、監管、商業性和貿易等多方面因素共同推動的。這項轉變本身既蘊含風險也蘊含機會。風險包括違規風險、聲譽壓力和潛在的成本影響。另一方面，機會包括市場差異化、透過針對性干預改善動物健康以及增強供應鏈韌性。那些採取策略性方法來應對這一轉變的企業——例如投資診斷技術、實現採購多元化、試點替代方案以及協調整個價值鏈的獎勵——將更有能力應對短期衝擊並確保長期競爭優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 食用動物非治療性抗生素市場：依動物類型分類

  • 水產養殖
  • 牛
  • 家禽
  • 豬

第9章 食用動物非治療性抗生素市場：依產品類型分類

  • Aminoglycosides
    • 慶大霉素
    • 新黴素
    • 鏈黴素
  • 大環內酯類
    • 紅黴素
    • 奇爾米考辛
    • 泰樂菌素
  • 青黴素類
    • 阿莫西林
    • Ampicillin
    • 青黴素G
  • 磺胺類藥物
    • 磺胺嘧啶
    • 磺胺二甲嗪
    • 磺胺甲噁唑
  • 四環黴素
    • 四環黴素
    • 四環黴素
    • 四環黴素

第10章 食用動物非治療性抗生素市場：以劑型分類

  • 飼料添加劑
  • 口服懸浮液
  • 水溶性粉末

第11章 食用動物非治療性抗生素市場（依給藥方式分類）

  • 飼料添加
  • 飲用水管理

第12章 食用動物非治療性抗生素市場：依最終用途分類

  • 促進生長
  • 預防

第13章 食用動物非治療性抗生素市場：依銷售管道分類

  • 飼料廠
  • 零售藥房
  • 獸藥批發商

第14章 食用動物非治療性抗生素市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 食用動物非治療性抗生素市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 食用動物非治療性抗生素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國非治療性動物用抗生素市場

第18章：中國食用動物非治療性抗生素市場。

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Huvepharma SA
  • Merck & Co., Inc.
  • Norbrook Laboratories Ltd.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-036C5CF3B529

The Non-Therapeutic Antibiotics for Food Animals Market was valued at USD 5.84 billion in 2025 and is projected to grow to USD 6.24 billion in 2026, with a CAGR of 7.27%, reaching USD 9.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.84 billion
Estimated Year [2026] USD 6.24 billion
Forecast Year [2032] USD 9.55 billion
CAGR (%) 7.27%

A strategic framing of the evolving scientific, regulatory, and commercial context that defines contemporary approaches to non-therapeutic antibiotic use in food animals

The global conversation around non-therapeutic antibiotics in food animal production has entered a more complex phase, shaped by evolving science, shifting consumer expectations, and heightened regulatory scrutiny. Stakeholders across the value chain are contending with the need to reconcile animal health management with antimicrobial stewardship principles, while sustaining productivity and supply continuity. This introduction lays out the context for the analysis that follows, highlighting the interplay between policy developments, industry responses, and commercial realities.

As science increasingly clarifies pathways for resistance and mitigations, producers and suppliers face expectations to adopt responsible use practices and alternatives to routine prophylactic and growth-promotion uses. At the same time, trade and input cost dynamics are influencing procurement and sourcing decisions, prompting supply chain actors to reassess procurement flexibility and supplier relationships. This section establishes a common baseline: non-therapeutic antibiotic use is no longer a narrow veterinary matter but a strategic risk and opportunity that intersects regulatory compliance, brand reputation, animal welfare, and operational resilience.

The remainder of this executive summary builds from this foundation to examine transformative market shifts, tariff-driven trade implications, segmentation-level nuances, regional dynamics, competitive intelligence, recommended actions, and research methodology. Throughout, emphasis is placed on evidence-based decision-making and practical levers organizations can deploy to navigate the transition toward reduced non-therapeutic antibiotic reliance while safeguarding animal productivity and business continuity.

How converging scientific evidence, consumer expectations, and technological advances are transforming stewardship practices and commercial strategies in food animal production

Recent years have seen a sequence of transformative shifts that are reshaping how non-therapeutic antibiotics are perceived, regulated, and used across animal agriculture. First, scientific consensus and surveillance data have elevated antimicrobial resistance from a niche concern to a cross-sectoral public health priority, prompting more robust stewardship frameworks and revised guidelines from veterinary and food safety authorities. Consequently, industry practices are adapting, with many large producers and retailers formalizing antibiotic use policies and accelerating trials of alternative interventions.

Second, consumer preferences are exerting palpable commercial pressure. Increased transparency demands and labeling expectations are incentivizing brands to differentiate through claims about antibiotic use, driving procurement changes and premium positioning for products aligned with stewardship goals. Third, technological advances in husbandry, rapid diagnostics, and vaccine development are expanding the toolkit available to reduce routine prophylactic use and to enable targeted therapeutic interventions. Adoption of these tools, however, varies by production system, scale, and capital intensity.

Finally, supply chain and trade dynamics are evolving in parallel. Vertical integration, contract production models, and retailer-led sourcing requirements are intensifying, while risk management strategies now routinely incorporate regulatory trajectory and reputational exposure. Taken together, these shifts create both operational challenges and strategic openings for firms that can deploy science-based stewardship, demonstrate supply chain traceability, and invest in scalable alternatives to non-therapeutic antibiotic use.

An assessment of how 2025 tariff adjustments have reshaped input sourcing, supply resilience, and the operational feasibility of stewardship investments across the value chain

Tariff policy adjustments enacted in 2025 have introduced additional complexity into the trade and supply equation for inputs and finished products related to animal production, influencing cost structures and sourcing decisions that indirectly affect patterns of non-therapeutic antibiotic use. Tariffs on certain veterinary inputs and on feed ingredient flows have altered relative prices, prompting some producers to reassess procurement geographies and to accelerate supply diversification strategies. These trade shifts are not isolated; they interact with domestic regulatory approaches and farm-level operational choices.

For producers with narrow margins or limited access to alternative inputs, tariff-induced cost pressures can constrain investments in stewardship-enhancing technologies such as rapid diagnostics, enhanced biosecurity infrastructure, or novel vaccine platforms. Conversely, companies with integrated supply chains or greater purchasing scale may seize the moment to reconfigure sourcing toward suppliers offering stewardship-compliant inputs, thereby strengthening long-term competitive positioning. Regional differences in tariff impacts have led to asymmetric responses, with some supply clusters accelerating domestic substitution while others deepen trade partnerships with low-cost suppliers.

Importantly, the tariff landscape has also influenced distributor and feed mill strategies. Distribution networks are adjusting inventories and contract terms to buffer volatility, while feed producers reevaluate formulations to maintain nutritional adequacy amid shifting ingredient prices. In the aggregate, the cumulative tariff effects of 2025 have heightened the strategic premium on resilience and adaptability, making proactive stewardship investments and supply chain redesign ever more salient for actors seeking to manage both compliance and commercial performance.

Segment-specific insights revealing how animal type, product classes, administration modes, end-use intents, formulation formats, and distribution channels determine stewardship pathways and adoption barriers

A granular segmentation lens reveals that pathways away from routine non-therapeutic antibiotic use differ markedly by animal type, product class, application mode, end use, formulation, and sales channel. Based on Animal Type, production systems such as Aquaculture, Cattle, Poultry, and Swine each present distinct epidemiology, management rhythms, and capital requirements that condition feasible stewardship interventions. Poultry and swine systems, which often operate at higher stocking densities and shorter production cycles, face different pressures and opportunities compared with cattle or aquaculture operations.

Based on Product Type, the landscape encompasses broad antibiotic classes including Aminoglycosides, Macrolides, Penicillins, Sulfonamides, and Tetracyclines, each with unique pharmacological properties, withdrawal considerations, and routes of historical use. Within Aminoglycosides, gentamicin, neomycin, and streptomycin have served targeted niches; among Macrolides, erythromycin, tilmicosin, and tylosin remain relevant in specific applications. Penicillins such as amoxicillin, ampicillin, and penicillin G continue to be widely employed therapeutically, while Sulfonamides including sulfadiazine, sulfamethazine, and sulfamethoxazole and Tetracyclines such as chlortetracycline, oxytetracycline, and tetracycline each contribute to distinct treatment paradigms. These product-level differences influence withdrawal planning, regulatory risk profiles, and the attractiveness of alternatives.

Based on Application Mode, the two dominant channels are in-feed and in-water administration, and each presents trade-offs for dosing precision, labor, and potential for lower-intensity prophylactic usage. Based on End Use, distinctions between Growth Promotion and Prophylaxis shape stakeholder incentives and regulatory scrutiny. Based on Formulation, feed additives, oral suspensions, and water soluble powders offer differing logistics, shelf-life, and ease of integration into husbandry routines. Finally, Based on Sales Channel, feed mills, retail pharmacies, and veterinary distributors play distinct roles in shaping access, advisory services, and compliance oversight. Understanding these segmentation layers is essential to designing targeted interventions, prioritizing R&D investments, and tailoring policy measures to the operational realities of different producer cohorts.

How regional regulatory frameworks, trade linkages, and production system diversity across the Americas, Europe Middle East & Africa, and Asia-Pacific shape stewardship trajectories and adoption pathways

Regional dynamics exert a strong influence on regulatory approaches, adoption of alternatives, and trade flows, resulting in differentiated strategic priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, an emphasis on consumer transparency and retailer-led sourcing has driven voluntary stewardship initiatives alongside national regulatory measures. North and South American producers are increasingly aligning procurement practices with buyer requirements and investing in traceability to maintain market access and brand differentiation.

In Europe, Middle East & Africa, regulatory frameworks tend to be prescriptive with firm controls on non-therapeutic uses, and enforcement mechanisms have matured in several European countries. This regulatory rigor has stimulated investment in alternatives, improved on-farm biosecurity practices, and tighter integration of veterinary oversight. By contrast, some MEA markets exhibit uneven regulatory enforcement and variable access to veterinary services, generating pockets of elevated risk and opportunity for targeted capacity-building.

Asia-Pacific encompasses a highly heterogeneous set of production systems and policy environments. Rapidly intensifying livestock sectors in parts of the region have created both pressure points around antibiotic use and fertile grounds for scaled alternative technologies. Trade linkages, feed ingredient sourcing, and input supply chains across the Asia-Pacific region interact with local regulatory trajectories, producing a mosaic of adoption rates and stewardship maturity. Understanding these regional contrasts is critical to designing interventions that are technically feasible, culturally appropriate, and economically sustainable.

Insights on competitive positioning and capability clusters that determine which companies can effectively commercialize alternatives and shape stewardship adoption across supply chains

Competitive dynamics and capability profiles among key industry players are reshaping how stewardship obligations translate into operational choices. Leading integrators and suppliers that combine product innovation with strong distribution networks are better positioned to offer bundled solutions that reduce reliance on routine non-therapeutic antibiotics. These actors typically invest in diagnostic services, vaccination programs, and nutrition-led interventions, enabling customers to transition with lower productivity disruption. Mid-sized regional players often compete on service proximity and pricing, and their success depends on aligning advisory capabilities with local husbandry practices.

Veterinary distributors and feed mill operators play pivotal intermediary roles by influencing on-farm access to products and guidance. Those that evolve from transactional sellers to consultative partners can help accelerate adoption of stewardship-friendly formulations and administration practices. Contract production models and branded retail channels are also important; companies with direct procurement influence can enforce supplier standards and catalyze investment in alternative technologies among upstream partners. New entrants offering rapid diagnostics, biosecurity platforms, or novel therapeutics can disrupt established supply patterns, while incumbent firms with deep customer relationships can leverage scale to commercialize alternatives more rapidly. Across the landscape, the winners will be those that integrate technical credibility, supply chain reach, and tailored commercial models to support customers through transition periods.

Practical, prioritized steps for executives to reduce routine antibiotic reliance while protecting productivity, including diagnostics, procurement realignment, and cross-value-chain collaboration

Industry leaders should prioritize a set of actionable measures that balance immediate compliance needs with longer-term resilience and competitiveness. First, invest in enhanced on-farm advisory services and rapid diagnostics to shift decision-making from blanket prophylaxis to targeted therapeutic interventions. This approach preserves animal health outcomes while reducing unnecessary exposure to antibiotics. Second, develop procurement strategies that diversify input sourcing and favor suppliers that provide verifiable stewardship credentials, thereby mitigating tariff-driven and geopolitical supply risks.

Third, accelerate pilots of non-antibiotic alternatives and husbandry innovations, coupling deployment with rigorous data collection to validate efficacy under commercial conditions. Fourth, strengthen collaboration across the value chain-engaging feed mills, veterinary distributors, retailers, and contract producers-to align incentives, clarify responsibility for compliance, and pool resources for training and infrastructure upgrades. Fifth, embed regulatory intelligence and scenario planning into commercial decision processes so that product portfolios and supply agreements remain adaptable to shifting rules and buyer requirements. Finally, communicate transparently with downstream customers and consumers about stewardship progress to build trust and differentiate responsibly. Implementing these measures requires cross-functional coordination and a mix of short-term operational fixes and sustained capability investments.

A transparent synthesis of literature review, stakeholder interviews, and triangulated qualitative analysis that supports the report's sectoral and operational conclusions

The research underpinning this executive summary combines secondary literature review, stakeholder interviews, and structured qualitative analysis to synthesize contemporary trends affecting non-therapeutic antibiotic use in food animal systems. Secondary sources included peer-reviewed scientific literature, regulatory guidance documents, industry white papers, and public surveillance reports to ensure alignment with the latest evidence on antimicrobial resistance, withdrawal protocols, and stewardship frameworks. Primary inputs were gathered through interviews with veterinarians, feed mill managers, distributor executives, producers across species, and trade specialists to capture operational realities and emergent practices.

Analytical methods prioritized triangulation: findings from interviews were cross-checked against regulatory developments and documented case studies to validate themes and identify divergent regional experiences. The segmentation and regional insights derive from mapping production system characteristics onto product usage patterns, distribution networks, and policy settings. While the methodology emphasizes qualitative depth and practical applicability, care was taken to ensure transparency about sources and to highlight areas where data gaps remain. Readers should consider the conclusions as directional and evidence-based, designed to inform strategy development and operational planning rather than to substitute for bespoke due-diligence in specific commercial contexts.

A conclusive synthesis emphasizing evidence-led strategies and collaborative pathways to reconcile stewardship goals with production and commercial imperatives

In conclusion, the trajectory away from routine non-therapeutic antibiotic use in food animal production is driven by an intersection of scientific, regulatory, commercial, and trade forces. Both risk and opportunity are embedded in this transition: risk in the form of compliance exposure, reputational pressures, and potential cost implications; opportunity in the form of market differentiation, improved animal health outcomes through targeted interventions, and strengthened supply chain resilience. Companies that approach the transition strategically-by investing in diagnostics, diversifying procurement, piloting alternatives, and aligning incentives across the value chain-will be better placed to manage short-term disruptions and secure long-term competitive advantage.

Critical to success will be an evidence-led approach that balances animal welfare, productivity, and public health considerations. Collaboration among producers, advisors, distributors, and buyers will accelerate practical solutions and reduce friction. Finally, iterative assessment of policy trajectories and trade dynamics, combined with flexible operational planning, will enable organizations to adapt as the landscape continues to evolve. The insights in this summary aim to support leaders in charting pragmatic pathways that uphold stewardship commitments while sustaining business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-Therapeutic Antibiotics for Food Animals Market, by Animal Type

  • 8.1. Aquaculture
  • 8.2. Cattle
  • 8.3. Poultry
  • 8.4. Swine

9. Non-Therapeutic Antibiotics for Food Animals Market, by Product Type

  • 9.1. Aminoglycosides
    • 9.1.1. Gentamicin
    • 9.1.2. Neomycin
    • 9.1.3. Streptomycin
  • 9.2. Macrolides
    • 9.2.1. Erythromycin
    • 9.2.2. Tilmicosin
    • 9.2.3. Tylosin
  • 9.3. Penicillins
    • 9.3.1. Amoxicillin
    • 9.3.2. Ampicillin
    • 9.3.3. Penicillin G
  • 9.4. Sulfonamides
    • 9.4.1. Sulfadiazine
    • 9.4.2. Sulfamethazine
    • 9.4.3. Sulfamethoxazole
  • 9.5. Tetracyclines
    • 9.5.1. Chlortetracycline
    • 9.5.2. Oxytetracycline
    • 9.5.3. Tetracycline

10. Non-Therapeutic Antibiotics for Food Animals Market, by Formulation

  • 10.1. Feed Additives
  • 10.2. Oral Suspensions
  • 10.3. Water Soluble Powders

11. Non-Therapeutic Antibiotics for Food Animals Market, by Application Mode

  • 11.1. In Feed
  • 11.2. In Water

12. Non-Therapeutic Antibiotics for Food Animals Market, by End Use

  • 12.1. Growth Promotion
  • 12.2. Prophylaxis

13. Non-Therapeutic Antibiotics for Food Animals Market, by Sales Channel

  • 13.1. Feed Mills
  • 13.2. Retail Pharmacies
  • 13.3. Veterinary Distributors

14. Non-Therapeutic Antibiotics for Food Animals Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Non-Therapeutic Antibiotics for Food Animals Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Non-Therapeutic Antibiotics for Food Animals Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Non-Therapeutic Antibiotics for Food Animals Market

18. China Non-Therapeutic Antibiotics for Food Animals Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Boehringer Ingelheim International GmbH
  • 19.6. Ceva Sante Animale S.A.
  • 19.7. Dechra Pharmaceuticals PLC
  • 19.8. Elanco Animal Health Incorporated
  • 19.9. Huvepharma S.A.
  • 19.10. Merck & Co., Inc.
  • 19.11. Norbrook Laboratories Ltd.
  • 19.12. Phibro Animal Health Corporation
  • 19.13. Vetoquinol S.A.
  • 19.14. Virbac S.A.
  • 19.15. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY NEOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY NEOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY STREPTOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY STREPTOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMOXICILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMOXICILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMOXICILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMPICILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMPICILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMPICILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLIN G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLIN G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLIN G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFADIAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFADIAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFADIAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFAMETHAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFAMETHAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFAMETHAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFAMETHOXAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFAMETHOXAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFAMETHOXAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY CHLORTETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY CHLORTETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY OXYTETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY OXYTETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY WATER SOLUBLE POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY WATER SOLUBLE POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY WATER SOLUBLE POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY IN FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY IN FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY IN FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY IN WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY IN WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY IN WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY GROWTH PROMOTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY GROWTH PROMOTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY GROWTH PROMOTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FEED MILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FEED MILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY APPLICATION MODE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. G7 NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. G7 NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 265. G7 NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 266. G7 NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 NON-THERAPEUTIC ANTIBIOTICS FOR FOOD ANIMALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 268. G